Actively Recruiting
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Led by Tempus AI · Updated on 2026-03-03
550
Participants Needed
5
Research Sites
509 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.
CONDITIONS
Official Title
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to participate in the research and provide biospecimens
- Willing and able to provide informed consent
- Have documented diagnosis of AML according to the World Health Organization (WHO) classification (Secondary AML allowed)
- Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)
- Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)
- For 002A subgroup: On active observation for about 6 months or intended for active observation
- For 002B subgroup: Intended for first line treatment and meets high risk criteria by FLIPI, GELF, or LDH above the upper limit of normal
- For 002C subgroup: Documented disease progression within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment
- For 002D subgroup: Pathologically confirmed transformation
You will not qualify if you...
- Not willing or able to adhere with the study procedures
- For AML cohort: Have received any prior therapy intended for standard of care treatment of AML
- For FL cohort 002A subgroup: Received prior treatment for follicular lymphoma
- For FL cohort 002A subgroup: Diagnosed with high risk follicular lymphoma by FLIPI High Risk, GELF High Tumor Burden, or LDH above ULN
- For FL cohort 002A subgroup: Resected patients with no evidence of disease
- For FL cohort 002B subgroup: Intended for active observation
- For FL cohort 002B subgroup: Received prior treatment for follicular lymphoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
The Center for Cancer and Blood Disorders
Bethesda, Maryland, United States, 20817
Actively Recruiting
2
Cancer Care Specialists of Reno
Reno, Nevada, United States, 89511
Actively Recruiting
3
Taylor Cancer Research Center
Maumee, Ohio, United States, 43537
Actively Recruiting
4
Cancer Care Associates of York
York, Pennsylvania, United States, 17403
Actively Recruiting
5
Avera Cancer Institue
Sioux Falls, South Dakota, United States, 57105
Actively Recruiting
Research Team
A
Aquarius Clinical Study Manager
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here